RU2009133793A - Лечение резистентных или невосприимчивых форм рака конъюгатами 7-этил-10-гидроксикампотецина с множеством ответвлений цепи - Google Patents

Лечение резистентных или невосприимчивых форм рака конъюгатами 7-этил-10-гидроксикампотецина с множеством ответвлений цепи Download PDF

Info

Publication number
RU2009133793A
RU2009133793A RU2009133793/15A RU2009133793A RU2009133793A RU 2009133793 A RU2009133793 A RU 2009133793A RU 2009133793/15 A RU2009133793/15 A RU 2009133793/15A RU 2009133793 A RU2009133793 A RU 2009133793A RU 2009133793 A RU2009133793 A RU 2009133793A
Authority
RU
Russia
Prior art keywords
cancer
resistant
acid
substituted
immune
Prior art date
Application number
RU2009133793/15A
Other languages
English (en)
Russian (ru)
Inventor
Хун ЧЖАО (US)
Хун Чжао
Пуджа САПРА (US)
Пуджа САПРА
Original Assignee
Энзон Фармасьютикалз, Инк. (Us)
Энзон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Энзон Фармасьютикалз, Инк. (Us), Энзон Фармасьютикалз, Инк. filed Critical Энзон Фармасьютикалз, Инк. (Us)
Publication of RU2009133793A publication Critical patent/RU2009133793A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
RU2009133793/15A 2007-02-09 2008-02-08 Лечение резистентных или невосприимчивых форм рака конъюгатами 7-этил-10-гидроксикампотецина с множеством ответвлений цепи RU2009133793A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90059207P 2007-02-09 2007-02-09
US60/900,592 2007-02-09

Publications (1)

Publication Number Publication Date
RU2009133793A true RU2009133793A (ru) 2011-03-20

Family

ID=39682430

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009133793/15A RU2009133793A (ru) 2007-02-09 2008-02-08 Лечение резистентных или невосприимчивых форм рака конъюгатами 7-этил-10-гидроксикампотецина с множеством ответвлений цепи

Country Status (13)

Country Link
US (2) US7928095B2 (enExample)
EP (1) EP2109448B1 (enExample)
JP (1) JP2010518120A (enExample)
KR (1) KR20090108082A (enExample)
CN (1) CN101605539B (enExample)
AU (1) AU2008213576B2 (enExample)
BR (1) BRPI0807232A2 (enExample)
CA (1) CA2677798A1 (enExample)
IL (1) IL200100A0 (enExample)
MX (1) MX2009008549A (enExample)
RU (1) RU2009133793A (enExample)
TW (1) TW200902066A (enExample)
WO (1) WO2008098178A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
EP2109448B1 (en) 2007-02-09 2013-09-11 Enzon Pharmaceuticals, Inc. Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
JP2011520983A (ja) * 2008-05-23 2011-07-21 エンゾン ファーマシューティカルズ，インコーポレーテッド オリゴヌクレオチドの送達のための細胞内遊離可能ジスルフィドリンカーを含有するポリマーシステム
WO2010025337A1 (en) * 2008-08-29 2010-03-04 Enzon Pharmaceuticals, Inc. Method of treating ras associated cancer
RS59607B1 (sr) * 2008-09-23 2020-01-31 Nektar Therapeutics Metod metronomskog doziranja kamptotecinskih prolekova (npr. peg-irinotekan)
JP2012506380A (ja) * 2008-10-21 2012-03-15 エンゾン ファーマシューティカルズ，インコーポレーテッド ７−エチル−１０−ヒドロキシカンプトテシンのマルチアーム型ポリマーコンジュゲートによる神経芽腫の治療
CA2758263A1 (en) * 2009-04-17 2010-10-21 Enzon Pharmaceuticals, Inc. Methods for inhibiting angiogenesis with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
BR112012001395A2 (pt) * 2009-07-22 2019-09-24 Enzon Pharmaceuticals Inc metodo para tratar um câncer her2 positivo em um mamifero metodo para aumentar os efetivos de antagonistas do receptor her2 em um mamifero apresentando um cancêr her2 positivo metodo para inibir o crescimento ou proliferação de células her2 positivas em um mamifero
CN104650342B (zh) * 2013-11-18 2018-07-10 江苏豪森药业集团有限公司 多支链聚合药物前体及其应用
CN103772696B (zh) * 2014-01-06 2015-12-02 济南大学 一种羟基喜树碱的聚甘油脂肪酸酯衍生物
CN110448533B (zh) * 2014-12-05 2022-03-29 天津键凯科技有限公司 一种聚乙二醇修饰的喜树碱类衍生物的药物组合物及其制备方法
CN108727584B (zh) * 2017-04-21 2021-01-05 博瑞生物医药（苏州）股份有限公司 抗癌偶联物
CN107670050B (zh) * 2017-08-30 2019-06-07 重庆阿普格雷生物科技有限公司 基于pki-587的抗癌中间体和聚乙二醇偶联抗癌药物、及其制备方法和应用
CN115052632B (zh) * 2020-01-15 2025-01-14 北京海步医药科技有限公司 靶向多肽-药物缀合物及其用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US4943579A (en) 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
WO1993024476A1 (en) 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5736156A (en) * 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
IL117684A (en) 1995-04-07 2002-02-10 Pharmacia & Upjohn Inc Intermediates and Process for Production of History of Kempotocin (CPT-11) and Related Compounds
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
JPH10168373A (ja) 1996-12-12 1998-06-23 Fuji Xerox Co Ltd インクジェット記録用インク及びそれを用いる記録方法
JP3855344B2 (ja) 1997-02-19 2006-12-06 日本油脂株式会社 ポリオキシアルキレンカルボン酸の製造方法
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
WO2000021370A1 (en) * 1998-10-14 2000-04-20 University Of Kentucky Research Foundation Oligonucleotide delivery systems for camptothecins
WO2000040755A2 (en) 1999-01-06 2000-07-13 Cornell Research Foundation, Inc. Method for accelerating identification of single nucleotide polymorphisms and alignment of clones in genomic sequencing
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6281223B1 (en) 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
AU772074B2 (en) 1999-04-28 2004-04-08 Vectramed, Inc. Enzymatically activated polymeric drug conjugates
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
MXPA02003719A (es) 1999-10-12 2002-08-30 Cell Therapeutics Inc Fabricacion de congujados de poliglutamato-agente terapeutico.
WO2001046291A1 (en) 1999-12-22 2001-06-28 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US20040009229A1 (en) 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
CA2402643A1 (en) 2000-03-17 2001-09-27 Cell Therapeutics, Inc. Polyglutamic acid-camptothecin conjugates and methods of preparation
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
JP2004514701A (ja) 2000-11-30 2004-05-20 ネクター　セラピューティクス　エーエル，コーポレイション トリアジン誘導体の水溶性ポリマー複合体
US20020123401A1 (en) * 2001-03-02 2002-09-05 Henry Rassem Ragheb Combination starter-generator
JP4123856B2 (ja) 2001-07-31 2008-07-23 日油株式会社 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法
WO2003033525A1 (en) 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
JP2005508365A (ja) 2001-10-29 2005-03-31 ネクター セラピューティックス エイエル，コーポレイション プロテインキナーゼｃインヒビターのポリマー結合体
ES2284959T3 (es) 2001-10-30 2007-11-16 Nektar Therapeutics Al, Corporation Conjugados polimericos solubles en agua de acido retinoico.
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
CN101843904A (zh) 2002-06-06 2010-09-29 华盛顿大学 使用青蒿素样化合物预防或延缓癌症显现的方法
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
US6649778B1 (en) 2002-09-20 2003-11-18 Enzon, Inc. Methods of preparing amino acid taxane derivatives and polymer conjugates containing the same
WO2004032925A1 (en) * 2002-10-11 2004-04-22 Novartis Ag Use of imatinib (glivec, sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents
AU2003301021C1 (en) 2002-12-16 2010-02-18 Globelmmune, Inc. Yeast-based vaccines as immunotherapy
DE60322111D1 (de) 2002-12-31 2008-08-21 Nektar Therapeutics Al Co Verfahren zur herstellung von hydrogelen aus thiosulfonat-zusammensetzungen und ihre verwendungen
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
CN1852740B (zh) * 2003-09-17 2011-05-11 耐科塔医药公司 多支链聚合物的药物前体
US20050214250A1 (en) 2003-11-06 2005-09-29 Harris J M Method of preparing carboxylic acid functionalized polymers
US9446139B2 (en) 2004-03-15 2016-09-20 Nektar Therapeutics Polymer-based compositions and conjugates of HIV entry inhibitors
US20070259375A1 (en) 2004-03-26 2007-11-08 Bristol-Myers Squibb Company Biomarkers and Methods for Determining Sensitivity to Epidermal Growth Factor Receptor Modulators in Non-Small Cell Lung Cancer
DE102005033392B4 (de) * 2005-07-16 2008-08-14 Center For Abrasives And Refractories Research & Development C.A.R.R.D. Gmbh Nanokristalline Sinterkörper auf Basis von Alpha-Aluminiumoxyd, Verfahren zu Herstellung sowie ihre Verwendung
US7989554B2 (en) 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
CA2640013A1 (en) 2006-02-09 2007-08-16 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
EP2109448B1 (en) 2007-02-09 2013-09-11 Enzon Pharmaceuticals, Inc. Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin

Also Published As

Publication number Publication date
AU2008213576A1 (en) 2008-08-14
KR20090108082A (ko) 2009-10-14
CA2677798A1 (en) 2008-08-14
AU2008213576A2 (en) 2009-09-03
EP2109448A2 (en) 2009-10-21
JP2010518120A (ja) 2010-05-27
IL200100A0 (en) 2010-04-15
WO2008098178A2 (en) 2008-08-14
CN101605539B (zh) 2013-01-02
EP2109448A4 (en) 2011-04-13
US7928095B2 (en) 2011-04-19
BRPI0807232A2 (pt) 2014-04-29
EP2109448B1 (en) 2013-09-11
MX2009008549A (es) 2009-08-18
WO2008098178A3 (en) 2008-12-24
AU2008213576B2 (en) 2013-01-17
US20110195990A1 (en) 2011-08-11
TW200902066A (en) 2009-01-16
US20080193408A1 (en) 2008-08-14
CN101605539A (zh) 2009-12-16

Similar Documents

Publication Publication Date Title
RU2009133793A (ru) Лечение резистентных или невосприимчивых форм рака конъюгатами 7-этил-10-гидроксикампотецина с множеством ответвлений цепи
JP2010518120A5 (enExample)
JP2009526076A5 (enExample)
ES2910941T3 (es) Ligandos de proteína de activación de fibroblastos para aplicaciones de administración dirigida
CN101784565B (zh) 含有亲水性间隔区接头的共轭物
CN115105607B (zh) 一种用于adc的双药-接头的制备方法及其用途
HRP20201790T1 (hr) Konjugati cisteinom izmijenjenih antitijela
HRP20160164T1 (hr) Citotoksiäśni derivati benzodiazepina
CN101678124A (zh) 结合配体连接的微管溶素递药缀合物
EP2908818A2 (en) Drug delivery conjugates containing unnatural amino acids and methods for using
ATE548357T1 (de) Gonadotropin freisetzende hormon rezeptor antagonisten und ihre verwandten verfahren
SG131943A1 (en) Specific binding agents to hepatocyte growth factor
RU2009102243A (ru) Производные камптотецина с противоопухолевой активностью
BRPI0716807A2 (pt) Tratamento de linfomas não-hodgkin com conjugados poliméricos multi-braço de 7-etil-10-hidroxicamptotecina
EP4291554A1 (en) Bivalent fibroblast activation protein ligands for targeted delivery applications
WO2014145718A2 (en) Peptides comprising non-natural amino acids and methods of making and using the same
CN106456796A (zh) 用于治疗耐药性癌症及用于联合治疗的药物递送缀合物
US20160303251A1 (en) Conjugates of garftase inhibitors
WO2006128674A8 (en) Combinations of indacaterol derivatives and other agents for the treatment of airway diseases
RU2008136209A (ru) Полиразветвленные полимерные конъюгаты 7-этил-10-гидроксикамптотецина для лечения рака молочной железы, яичников и легких
CN120390747A (zh) 用于靶向递送应用的碳酸酐酶ix配体
CN120344548A (zh) 生长抑素亚型-2受体(sst2r)靶向治疗药物及其用途
RU2009114156A (ru) Лечение неходжкинских лимфом с помощью разветвленных полимерных конъюгатов 7-этил-10-гидроксикамптотецина
CN116917278A (zh) 用于靶向递送应用的二价成纤维细胞活化蛋白配体
WO2018200921A1 (en) Peptides for cancer treatment